Kornimate/medical-research-clean huggingface dataset:
prediction model of microvascular ischemic ocular motor nerve palsy and inflammatory ocular motor nerve palsy in chinese patients

Conditions: Neuro-Ophthalmology

Summary: this study aimed to train and validate deep learning systems (dls) to differentiate between microvascular ischemic ocular motor nerve palsy (v-omnp) and inflammatory ocular motor nerve palsy (i-omnp). the method involves using clearly diagnosed v-omnp and i-omnp patients from the department of neurology database at beijing tongren hospital for further dls validation, aiding in the differential diagnosis of the aforementioned diseases.


Eligibility criteria:
the diagnosis of disease is the outcome of the study. the inclusion criteria and exclusion criteria were as follows: 1. inclusion criteria: * patients with acute bilateral diplopia within 1 week of onset at admission. 1. ischemic group: 1. sudden onset of unilateral cn iii, cn iv, or cn vi palsy. 2. isolated cn iii (without pupil involvement), cn iv, or cn vi palsy. 3. presence of vascular risk factors (vrfs). 4. significant symptom recovery no earlier than 2 months after onset, with complete (or nearly complete) recovery within 3-6 months. 2. inflammatory group: 1. unilateral painful cn iii, cn iv, and/or cn vi palsy. 2. symptoms (including pain or diplopia signs) significantly improved within 72 hours after treatment with corticosteroids. 3. mri of the cavernous sinus showing inflammation, i.e., abnormal widening/enhancement of the affected cavernous sinus with or without granulomatous changes/inflammatory manifestations of adjacent tissues. 2. exclusion criteria: * 1. ocular muscle palsy confirmed to be caused by tumors, trauma, infections, stroke, carotid-cavernous fistula, aneurysms, neuromuscular junction disorders, thyroid-related eye diseases, and hereditary diseases at onset or during follow-up. 2. presence of other neurological signs in addition to ocular muscle palsy. 3. severe systemic diseases of the heart, liver, or kidneys, as well as psychiatric and mental illness. 4. pregnant or breastfeeding patients. 5. patients who did not undergo gadolinium-enhanced mri of the cavernous sinus. 6. patients younger than 18 years at the time of enrollment. 7. onset of symptoms more than 1 week before admission. 8. incomplete data or follow-up period less than 6 months. 9. disagreements in disease diagnosis.
anlotinib combined with nivolumab for non-small cell lung cancer

Conditions: Non Small Cell Lung Cancer

Summary: this study evaluates the safety and efficacy of anlotinib in combination with nivilumab as second-line treatment in advanced nsclc patients. the primary endpoint of the study is progression-free survival (pfs);the secondary endpoints are disease control rate (dcr), objective response rate (orr), overall survival (os) and safety.


Eligibility criteria:
inclusion criteria: 1. male or female patients aged 18-75 years old; 2. ecog ps：0-1,expected survival time: over 3 months; 3. subjects with histologically or cytologically confirmed locally advanced and/or advanced nsclc, with measurable nidus(using recist 1.1); 4. for local advanced or advanced nsclc, disease progression occurred after first-line systemic treatment previously; 5. the negative patients in egfr\&alk can participate or who positive in egfr\&alk, have or have not drug tolerance after the treatment with relative targeted drugs; 6. main organs function is normal; 7. signed and dated informed consent. exclusion criteria: 1. have used anlotinib before; 2. small cell lung cancer (including small cell cancer and other kinds of cancer mixed with non-small cell cancer); 3. examined as positive in egfr\&alk mutation detection and never take the treatment of tkis; 4. previously (within 5 years) or presently suffering from other malignancies; 5. symptomatic or uncontrolled brain metastases; 6. unstable systemic disease, including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months or serious cardiac arrhythmia requiring medication; 7. pregnancy or lactation.
oral omadacycline vs. oral nitrofurantoin for the treatment of cystitis

Conditions: Uncomplicated Urinary Tract Infection; Cystitis

Summary: the purpose of this study is to evaluate the safety and efficacy of oral omadacycline as compared to oral nitrofurantoin in the treatment of female adults with cystitis.

participants were randomized to receive 7 days of treatment of either omadacycline or nitrofurantoin. the end of treatment visit, post therapy evaluation visit, and final follow-up visit was planned within 2 days following the last dose of study drug, on day 14 (+/- 2 days) after the first dose of study drug, and within 30 to 37 days following the first dose of study drug, respectively. the study followed a double-dummy design. to maintain the study blinding, participants assigned to omadacycline received active omadacycline tablets and over-encapsulated nitrofurantoin placebo tablets. participants assigned to the nitrofurantoin arm received omadacycline placebo tablets and over-encapsulated active nitrofurantoin capsules.

Eligibility criteria:
inclusion criteria: * female participants, age 18 or older who have signed the informed consent form * must have a qualifying uncomplicated urinary tract infection * participants must not be pregnant at the time of enrollment * must agree to a reliable method of birth control during the study and for 30 days following the last dose of study drug exclusion criteria: * males * evidence of complicated urinary tract infection (uti), upper uti, vaginitis, or sexually transmitted infection * evidence of significant immunological disease * has received an investigational drug within the past 30 days * participants who are pregnant or nursing
study of telbivudine in chronic hepatitis b

Conditions: Chronic Hepatitis B

Summary: the purpose of this study is to evaluate the safety, tolerability and antiviral efficacy of telbivudine by maintained suppression of hepatitis b virus (hbv) dna (\<=300 copies/ml or 60iu/ml, undetectable by current polymerase chain reaction (pcr) - based assays) in hbeag positive/negative patients at physician's general practice.

primary objective: to evaluate the antiviral efficacy of telbivudine by maintained suppression of hbv dna(\<=300 copies/ml or 60 iu/ml,undetectable by current pcr-based assays) in hbeag positive patients from week 24 to week 48. methodology: this will be an open-label, prospective, observational, single-center and single arm post marketing surveillance study. number of patients: it is estimated to enroll 240 intent-to-treat patients in taiwan. population: male or female patients, at least 18 years of age diagnosed with chronic hepatitis b with liver disease and telbivudine is prescribed by physicians based on clinical justification. and patients are able to communicate well, provide written informed consent, and willing to participate in the entire study.

Eligibility criteria:
inclusion criteria: 1. male or female, at least 18 years of age. 2. documented chronic hepatitis b defined by all of the following: * clinical history compatible with chronic hepatitis b. * detectable serum hepatitis b surface antigen \>= 6 months at screening visit, with either hbeag positive or negative. 3. willing and able to comply with the observational drug regimen and all other study requirements. 4. willing and able to provide written informed consent to participate in the study. exclusion criteria: 1. females who are pregnant,intending to become pregnant or breast feeding. 2. patients with co-infection with hepatitis c virus, hepatitis d virus or human immunodeficiency virus. 3. patients with hypersensitivity to telbivudine or to any of the excipients. 4. one or more known primary or secondary causes of liver disease other than hepatitis b (e.g., alcoholism, steatohepatitis, autoimmune hepatitis, hemochromatosis, alpha-1 anti-trypsin deficiency, wilson's disease, other congenital or metabolic conditions affecting the liver, congestive heart failure or other severe cardiopulmonary disease). gilbert's syndrome and dubin-johnson syndrome will not exclude patients from participation in this trial. 5. enrolled or planning to be enrolled in another clinical trial of an investigational agent while participating in this study. 6. unable to receive safety and tolerability assessments.

Keywords: hbv dna non-detectability
evaluation of five selected markers in skin biopsies of patients with postherpetic neuralgia and healthy controls

Conditions: Postherpetic Neuralgia; Healthy Age/Gender Matched Volunteers

Summary: postherpetic neuralgia is a painful nerve condition that can occur when nerve fibers are damaged following an outbreak of shingles. the purpose of this study is to identify and study abnormalities in the nerves and cells in the of patients with postherpetic neuralgia (phn) and characterize changes that could be responsible for causing nerve pain. this data will be compared to the tissue of healthy volunteers. our goal is that this information will lead to the development of better treatment options for people with painful nerve conditions.


Eligibility criteria:
inclusion criteria: group 1: 5 caucasian males \>50 years of age with phn of greater than 6 months duration since rash healed and clinically meaningful pain (visual analog scale (vas) \>40mm at baseline) group 2: 5 caucasian males \>50 years of age, non-diabetic with no nervous system disease (healthy control groups) exclusion criteria: 1. history of clinically significant liver disease, serious peripheral vascular disease, a blood clotting disorder, or any other medical condition felt to be exclusionary by the investigator 2. allergy to lidocaine 3. unwillingness to sign informed consent or any other reasons for which the investigator feels the subject cannot complete the study 4. history of slow-healing diabetic foot ulcers 5. hga1c \>11% within the last three months 6. active cancer within the previous two years, except treated basal cell carcinoma of the skin 7. co-morbidities that can produce neuropathy 8. subjects taking sodium channel blockers within one week of study treatment and throughout the study 9. subjects taking any other experimental drugs within 30 days prior to enrollment 10. application of lidocaine patch to either foot or to phn site within two weeks of enrollment
non-invasive electrical stimulation of the human brain

Conditions: Cerebrovascular Disorders; Healthy; Nervous System Diseases; Spinal Cord Injuries

Summary: this study is designed to allow researchers to use transelectrical stimulation to explore the function of the human nervous system and improve diagnosis of neurological disorders. transcranial electrical stimulation is a non-invasive technique that can be used to stimulate brain activity and gather information about brain function. electrical stimulation involves placing electrodes on the scalp or skin and passing an electrical current between them. when this is done, an electrical field is created that activates areas of the brain that control muscles. muscle activity as a result of the stimulation can be recorded and analyzed.

this protocol application is written to permit us to use transcranial electrical stimulation, a safe and noninvasive method for activating the brain, spinal cord, or proximal nerves through the skin, in appropriate subjects. we will use this technique to explore the function of the human central and peripheral nervous system and to aid in the diagnosis of neurological disorders.

Eligibility criteria:
males and females, ages 18 and over. diverse racial groups. amputees and others with whom we will have no patient-care relationship may also be considered to be volunteers. patients will be recruited from those referred to the human motor control section, ninds who have neurological syndromes that are of interest. on rare occasions we may attempt to study children as young as 10 years with tes. individuals without indwelling cardiac lines and pacemakers. patients recruited for study would come from those referred to the emg laboratory and to the human motor control clinic who would have distinct neurologic syndromes from well defined peripheral and central nervous system lesions including hemiplegia from stroke, trauma, tumor or focal demyelination (most commonly patients would have hemiplegia from stroke), peripheral nerve lesions, amputations, spinal cord injury. normal volunteers, including nih employees, would be healthy adults without history of physical examination evidence of neurologic disease and individuals with different types of amputations involving upper and lower extremities. volunteers may also be participants in the electrophysiological protocol (84-n-0196). no history of epilepsy.

Keywords: amputations brainstem stimulation cerebellar stimulation cortical motor physiology electrical stimulation motor cortex plasticity spinal cord injury stroke
joint effort study

Conditions: Cannabis Use

Summary: this pilot randomized controlled trial (rct) will be conducted to evaluate the acceptability and feasibility of a digital tailored prevention tool (i.e., the joint effort mobile application) aimed at supporting university-level students into taking action on their cannabis use. the two main objectives of the proposed study are: 1. to assess the acceptability of the joint effort mobile application in terms of uptake, engagement and intervention appreciation. 2. to document the feasibility of the study processes in terms of online recruitment rate, adherence to online data collection methods, and attrition rate.


Eligibility criteria:
inclusion criteria: * active cannabis user (i.e., having used cannabis at least once in the past month) * able to understand french * own an iphone (running on ios 13 or higher).
nebivolol and endothelial regulation of fibrinolysis (nerf)

Conditions: Prehypertension; Hypertension

Summary: the investigators hypothesize that nebivolol will improve endothelial t-pa release in adult humans with elevated blood pressure to a greater extent than either metoprolol or placebo. the investigators further hypothesize that the improvement in the capacity of the vascular endothelium to release t-pa with nebivolol is mediated, in part, by the compound's antioxidant properties.


Eligibility criteria:
inclusion criteria: * subjects will be men and women of all races and ethnic backgrounds aged 45-65 years. * subjects will be prehypertensive/hypertensive defined as resting systolic blood pressure \>125 mmhg and \ 80 mmhg and \<100 mmhg. * all of the women in the study will be postmenopausal and not receiving hormone replacement therapy (hrt) currently or in the preceding 3-year period. * candidates will be sedentary as determined from the stanford physical activity questionnaire (\<35 kcal/wk) and will not have engaged in any program of regular physical activity for at least 1 year prior to the study. exclusion criteria: * candidates who smoke (currently or in the past 7 years), report more than low-risk alcohol consumption as defined as no more than 14 standard drinks/wk and no more than 4 standard drinks/day for men and 7 standard drinks/wk and 3 standard drinks/day for women (a standard drink is defined as 12 ounces of beer, 5 ounces of wine, 1½ ounces of 80-proof distilled spirits). * potential candidates who are taking cardiovascular-acting (i.e. statins, blood pressure medication and aspirin) medications will not be eligible. * fasting plasma glucose \>126 mg/dl. * potential candidates with a resting heart rate of \< 50 beats/minute will be excluded. * use of hormone replacement therapy. * in hypertensive subjects, a seated systolic blood pressure \>160 mmhg or a seated diastolic blood pressure \>100 mmhg will be excluded.
study of sta-9090, administered twice-weekly in patients with solid tumors

Conditions: Solid Tumors

Summary: an open-label dose escalation study of patients with solid tumors treated with sta-9090 (ganetespib)

this is an open-label phase 1 dose-escalation study in patients with solid tumors treated with sta-9090 (ganetespib) to evaluate for safety, tolerance and efficacy.

Eligibility criteria:
inclusion criteria: * patients must be documented to be refractory or not candidates for current approved therapies. - must have anecog status 0-2. - peripheral neuropathy ?2. * must have acceptable organ and marrow function per protocol parameters. * no clinically significant ventricular arrythmias or ischemia. exclusion criteria: * must not be pregnant or breastfeeding. -no chemotherapy or radiation within 3 weeks.. * no previous radiation to \>25% of total bone marrow. * no previous high dose chemotherapy with autologous or allogeniec hematopoietic stem cell transplantation. * no primary brain tumors or active brain metastases. * no use of any investigational agents within 4 weeks. * no treatment with chronic immunosuppressants. * no uncontrolled, intercurrent illness.

Keywords: metastatic cancer solid tumor histologically or cytologically confirmed non-hematological malignancy that is metastatic or unresectable sta-9090 ganetespib
efficacy and safety of rivaroxaban in reducing the risk of major thrombotic vascular events in subjects with symptomatic peripheral artery disease undergoing peripheral revascularization procedures of the lower extremities

Conditions: Peripheral Artery Disease

Summary: the purpose of study was to test whether rivaroxaban added to standard of care treatment, when compared to placebo, had the potential to reduce the incidence of the clinical events related to the clots and complications of the heart and brain (cv death, mi, or stroke) or the legs (acute limb ischemia or major amputation) in patients who had undergone recent procedure(s) to improve the blood flow of their legs.


Eligibility criteria:
inclusion criteria: * age ≥50 * documented moderate to severe symptomatic lower extremity atherosclerotic peripheral artery disease * technically successful peripheral revascularization distal to the external iliac artery for symptomatic pad (peripheral artery disease) within the last 10 days prior to randomization exclusion criteria: * patients undergoing revascularization for asymptomatic pad or mild claudication without functional limitation of the index leg. * patients undergoing revascularization of the index leg to treat an asymptomatic or minimally symptomatic restenosis of a bypass graft or target lesion restenosis. * prior revascularization on the index leg within 10 days of the qualifying revascularization. * planned dual antiplatelet therapy (dapt) use for the qualifying revascularization procedure of clopidogrel in addition to acetylic salicylic acid (asa) for \>6 months after the qualifying revascularization procedure; it is strongly recommended that any course of clopidogrel is kept to the minimum necessary in accordance with local standard of care and international practice guidelines (typically 30 days, or up to 60 days for some drug-coated products or devices) and is only allowed for up to 6 months for complex procedures or devices in the investigator's opinion that require longer use. * planned use of any additional antiplatelet agent other than clopidogrel and asa after the qualifying revascularization procedure.

Keywords: rivaroxaban xarelto aspirin acetylic salicylic acid anticoagulant peripheral artery disease peripheral arterial disease revascularization acute limb ischemia amputation cardiovascular events
intracervical block during laminaria insertion

Conditions: Late Abortion; Dilation and Evacuation

Summary: whether intracervical block with lidocaine 1% is superior to sham procedure - intracervical injection of saline 0.9% - in terms of pain control.

* research design - double-blind randomized study * study population - women who are candidates for late termination of pregnancy by dilation and evacuation and approach for the insertion of laminaria will be recruited for the study. * the women will be divided into two groups * research group - women who will undergo preparation for the insertion of laminaria by anesthesia with lidocaine spray, followed by an intracervical injection of 1% lidocaine. * control group - women who will be anesthetized with lidocaine spray + intracervical injection of an inactive substance (0.9% saline). * randomization will be performed using dedicated computer software according to blocks of 2-6 women. * all women will be offered to take 400 mg of ibuprofen about half an hour before the procedure. * in the research group - a 10 ml syringe will be filled with 7 ml of lidocaine and 1 ml of bicarbonate (total 70 mg of lidocaine). * in the control group - a 10 ml syringe will be filled with 8 ml of 0.9% nacl saline. * primary anesthesia will be performed using 10% lidocaine spray in up to 5 sprays. * injection into the cervix will be performed at 3, 6, 9, 12 o'clock positions, after prior aspiration, with a 23-gauge needle, about 2 ml per point. * laminaria type to be inserted - "small" diameter 3 mm, length 6.5 cm (medgyn: lombard, il, usa, and norscan: westlake village, ca, usa). * at weeks 18-20, 7-9 laminaria will be inserted. * over 20 weeks - over 10 laminaria will be inserted. * number of participants in the study - 70.

Eligibility criteria:
inclusion criteria: * voluntary termination of pregnancy approved by a committee or missed abortion * 18.0 to 22.5 gestational week (the gestational age in the case of a missed abortion is determined by the bpd - biparietal diameter, which is the determining measure for the ability to perform d\&e.) * singleton pregnancy exclusion criteria: * multiple pregnancy * women undergoing the procedure urgently due to cervical insufficiency, inevitable abortion, premature rupture of membranes, or suspected chorioamnionitis * allergy to lidocaine * women who do not speak hebrew or english * women who have a guardian for any reason * women with a history of cesarean section * women with abnormal placental implantation, such as placenta previa or suspected placenta accreta * women with a psychiatric illness * women with a history of alcoholism or drug abuse * women who required a "two-stage" laminaria insertion will not be included in the analysis. in cases where the cervix does not allow the insertion of the required number of laminaria, the process is carried out in two stages: in the first stage, the maximum possible number is inserted, the woman is hospitalized, and after a few hours when some initial dilation of the cervix has occurred, the laminaria are removed and new ones are inserted according to the required number